List of Excipients in Branded Drug SPIKEVAX

« Back to Dashboard

SPIKEVAX Excipient Strategy, Lipid Nanoparticle Patents, and Commercial Opportunities

Last updated: October 9, 2026

Spikevax is a lipid nanoparticle mRNA vaccine whose commercial value depends on more than the mRNA sequence. Its excipient system controls cellular delivery, stability, tolerability, manufacturing yield, storage, and freedom to operate. The core formulation uses four functional lipid components, a buffering system, sucrose, and water for injection. The largest commercial opportunities are in ionizable lipids, PEG-lipids, lipid raw-material quality, analytical testing, sterile fill-finish, and improved thermostability.

The excipient composition is publicly disclosed in the FDA prescribing information and European Medicines Agency product information. The principal formulation components are SM-102, PEG2000-DMG, DSPC, cholesterol, tromethamine, tromethamine hydrochloride, acetic acid, sodium acetate trihydrate, sucrose, and water for injection (FDA, 2024; EMA, 2024).

What excipients are used in Spikevax?

Spikevax uses a four-lipid nanoparticle system surrounded by a buffered aqueous formulation.

Excipient	Functional role	Commercial significance
SM-102	Ionizable lipid that promotes mRNA encapsulation and endosomal release	Core delivery technology and principal IP risk
PEG2000-DMG	PEG-lipid that controls particle formation, size, and colloidal stability	Key contributor to particle behavior and repeat-dose tolerability
DSPC	Structural phospholipid forming the nanoparticle membrane	Established pharmaceutical lipid with multiple qualified suppliers
Cholesterol	Supports membrane structure, fluidity, and nanoparticle stability	Commodity-like input but subject to pharmaceutical-grade qualification
Tromethamine	Primary buffer	Controls formulation pH
Tromethamine hydrochloride	Counterion and buffer component	Supports pH and osmolality control
Acetic acid	pH adjustment	Low-cost formulation component
Sodium acetate trihydrate	Buffer and ionic-strength control	Commodity excipient with pharmaceutical-grade supply requirements
Sucrose	Cryo- and lyoprotective stabilizer	Supports mRNA and nanoparticle integrity during freezing and thawing
Water for injection	Vehicle	Sterile manufacturing input

SM-102 is the most strategically important excipient. It is an ionizable lipid designed to remain relatively neutral at physiological pH while becoming positively charged in the acidic environment used during nanoparticle formation and after cellular uptake. That behavior supports mRNA encapsulation and intracellular release.

The final product is not a simple solution of mRNA and excipients. It is a controlled colloidal system. Particle size, polydispersity, encapsulation efficiency, lipid-to-mRNA ratio, residual solvent levels, free lipid, RNA integrity, and potency are critical quality attributes.

How does the Spikevax lipid nanoparticle formulation work?

Spikevax uses a solvent-mixing process in which the mRNA-containing aqueous phase is combined with an organic lipid phase. The ionizable lipid interacts with the negatively charged mRNA during mixing. DSPC and cholesterol provide structural support, while PEG2000-DMG limits uncontrolled particle growth and aggregation.

The formulation strategy has four technical objectives:

1. Encapsulate mRNA at high efficiency.
2. Produce a narrow particle-size distribution.
3. Protect mRNA during frozen storage and transport.
4. Release sufficient mRNA inside cells to produce antigen.

The excipient system creates several development constraints. Changes to the ionizable lipid can alter potency and tolerability. Changes to PEG-lipid concentration can affect particle size, circulation behavior, aggregation, and anti-PEG immune responses. Changes to sucrose or buffer composition can affect freeze-thaw stability. Substitution of DSPC or cholesterol can require comparability work even if the replacement material has the same compendial identity.

For developers, the formulation is therefore protected through a combination of composition, process, analytical, and performance parameters rather than through a single ingredient claim.

What formulations are protected by Spikevax patents?

The relevant patent estate is likely to cover multiple layers:

Ionizable lipid composition

Patents may claim SM-102 or structurally related ionizable lipids, including their use in nucleic-acid delivery. These claims can reach the lipid itself, lipid libraries, salts, stereoisomers, pharmaceutical compositions, and methods of delivering mRNA.

Lipid nanoparticle composition

Claims may cover specific molar ratios of ionizable lipid, phospholipid, cholesterol, and PEG-lipid. Particle size, encapsulation efficiency, charge characteristics, and nucleic-acid payload can appear as claim limitations.

mRNA delivery and vaccination

Method-of-use claims may cover administering an mRNA-lipid nanoparticle to induce an immune response against SARS-CoV-2 or other antigens. These claims can remain relevant after composition claims narrow or expire.

Manufacturing methods

Process claims may address rapid mixing, lipid-to-RNA ratios, solvent exchange, concentration, filtration, sterile filling, and frozen storage. Manufacturing claims are commercially important because a competitor may avoid a composition claim but still infringe a process claim.

A representative Moderna patent relevant to the lipid nanoparticle platform is U.S. Patent No. 10,702,600, titled "Lipid nanoparticles for delivery of nucleic acids." Its patent family illustrates the platform-level approach used to protect ionizable-lipid delivery systems (U.S. Patent and Trademark Office, 2020). The complete Spikevax estate requires a family-by-family review of granted claims, terminal disclaimers, patent-term adjustment, prosecution history, and jurisdiction-specific status.

How many patents cover Spikevax?

A precise count depends on the search method. A count of documents can materially overstate protection because one invention may appear as a U.S. application, continuation, divisional, international application, and foreign national filing.

For commercial analysis, the estate should be separated into five groups:

Patent group	Relevant subject matter	Risk to a generic or biosimilar entrant
Platform lipid patents	Ionizable lipids and lipid combinations	High
Product-composition patents	SM-102, PEG2000-DMG, DSPC, cholesterol, and mRNA	High
Manufacturing patents	Mixing, encapsulation, purification, and fill-finish	Medium to high
Method-of-use patents	Vaccination, boosting, age groups, and dosing	Medium
Formulation-stability patents	Frozen storage, thawing, concentration, and container closure	Medium

The strongest blocking position usually comes from granted composition claims covering the ionizable lipid and the lipid nanoparticle rather than from narrow use claims. Patent strength should be measured by claim breadth, remaining term, validity risk, design-around options, and the ability to prove infringement from publicly available product or process information.

When does Spikevax lose exclusivity?

Spikevax has several separate exclusivity layers.

Exclusivity layer	Relevant date or status
U.S. Emergency Use Authorization	December 18, 2020
U.S. BLA approval	January 31, 2022
Reference-product biologic exclusivity	Generally 12 years from BLA approval under U.S. law
Earliest ordinary U.S. biosimilar approval pathway	Generally no earlier than January 31, 2034, subject to statutory rules
Patent exclusivity	Depends on each patent family, terminal disclaimers, and patent-term adjustment
Pediatric exclusivity	Potentially six additional months only if FDA grants it for qualifying studies
European regulatory protection	Depends on the applicable centralized authorization and supplementary protection rules

Spikevax is a biologic vaccine, not a conventional small-molecule drug. It is not listed in the FDA Orange Book in the same manner as an approved tablet or injectable small molecule. Biologic reference products and biosimilar applications are tracked through the Purple Book framework rather than the Orange Book patent-listing system (FDA, 2024a).

The practical result is that an entrant cannot rely on an Orange Book-style automatic 30-month stay based on a listed patent. Patent litigation, regulatory exclusivity, manufacturing capability, and product comparability become more important.

What is the Orange Book and Purple Book status of Spikevax?

Spikevax does not have a conventional Orange Book patent listing because it was approved under a biologics license application. Its relevant regulatory reference-product status is associated with the FDA Purple Book and the BLA framework.

The distinction matters:

• A generic applicant typically uses an abbreviated new drug application.
• A biosimilar applicant uses a 351(k) biologics license application.
• A biosimilar applicant must demonstrate high similarity and no clinically meaningful differences from the reference product.
• The applicant must also manage patent-certification and litigation provisions under the Biologics Price Competition and Innovation Act.

For Spikevax, a biosimilar developer would need to address both analytical similarity and a potentially complex intellectual-property estate covering mRNA delivery, lipid composition, manufacturing, and use.

Which companies are challenging Spikevax patents?

Publicly disclosed patent activity has primarily involved broader mRNA and lipid nanoparticle disputes rather than a mature group of companies preparing a commercial Spikevax biosimilar.

The principal competitive and litigation categories are:

Pfizer and BioNTech

Moderna has pursued patent disputes involving mRNA vaccine technology and lipid nanoparticle technology against Pfizer and BioNTech. Those disputes are relevant to the freedom-to-operate position of the entire COVID-19 mRNA vaccine market, although they do not automatically establish infringement by a Spikevax substitute or determine the validity of every Moderna patent.

Arbutus and Genevant

Arbutus Biopharma and Genevant Sciences have developed and enforced lipid nanoparticle patent positions relevant to nucleic-acid delivery. Their technology is commercially important because overlapping lipid nanoparticle claims can create licensing exposure even when a competitor uses a different ionizable lipid.

Biosimilar developers

No broad, established U.S. market of interchangeable or approved Spikevax biosimilars has emerged in the public regulatory record. Future entrants are more likely to begin with regional or public-sector opportunities, updated strain products, or alternative mRNA vaccines rather than a direct U.S. biosimilar launch.

What Paragraph IV challenges apply to Spikevax?

Paragraph IV certification is a Hatch-Waxman mechanism for small-molecule ANDAs. It does not provide the primary framework for challenging a biologic such as Spikevax.

A Spikevax competitor would instead use the biologics pathway. Relevant actions may include:

• Patent invalidity or noninfringement litigation.
• Declaratory-judgment actions.
• BPCIA patent-exchange procedures.
• Opposition or revocation actions in Europe.
• Patent-term and supplementary-protection-certificate challenges.
• Freedom-to-operate strategies based on alternative lipid compositions.

A company seeking to commercialize an updated COVID-19 mRNA vaccine may also pursue its own BLA rather than a biosimilar application. That route can avoid some reference-product comparability obligations but does not eliminate patent risk.

What commercial opportunities exist in Spikevax excipients?

The largest commercial opportunities are upstream and process-oriented.

Ionizable lipid supply

SM-102 and related lipids require specialized synthesis, purification, analytical characterization, and scale-up. Suppliers can compete through:

• GMP-grade lipid manufacturing.
• Stable isotope or impurity standards.
• Route optimization.
• Lower residual-solvent profiles.
• Improved batch consistency.
• Dual-source qualification.
• Regional manufacturing capacity.

The principal barrier is not chemical synthesis alone. It is reproducible production at pharmaceutical quality with a validated impurity profile.

PEG-lipid alternatives

PEG2000-DMG is a relatively small component by mass but has an outsized effect on nanoparticle behavior. Commercial opportunities include alternative PEG-lipids, cleavable PEG-lipids, biodegradable PEG architectures, and materials designed to reduce anti-PEG effects.

Any substitute must demonstrate comparable particle formation, potency, stability, tolerability, and manufacturability. A lower-cost PEG-lipid without comparable performance has limited value.

DSPC and cholesterol

DSPC and cholesterol are less differentiated than SM-102. Their commercial opportunity lies in reliable pharmaceutical-grade supply, low endotoxin levels, trace-metal control, oxidation control, and validated storage. Suppliers with multiple manufacturing sites can create value because vaccine manufacturers need continuity of supply during demand surges.

Analytical testing

Specialist laboratories can support:

• Lipid identity and purity.
• mRNA integrity.
• Encapsulation efficiency.
• Particle size and polydispersity.
• Residual solvents.
• Free lipid and degradants.
• Potency and antigen expression.
• Container-closure integrity.

Analytical methods are a recurring revenue opportunity because every formulation change, supplier change, and process transfer requires comparability testing.

Thermostability and alternative presentations

The current frozen supply chain creates cost and access constraints. Commercially valuable innovations include:

• Refrigerated liquid formulations.
• Lyophilized or dried lipid nanoparticles.
• More concentrated multidose presentations.
• Prefilled syringes.
• Reduced-volume pediatric doses.
• Improved vial and stopper systems.
• Less temperature-sensitive packaging.

The patent opportunity is strongest where a formulation improvement has measurable stability and manufacturing benefits without copying the exact Spikevax composition.

How strong is the Spikevax patent estate?

The estate is strongest in the core lipid nanoparticle platform and ionizable-lipid chemistry. It is less predictable for broad method-of-use claims because prior art in mRNA vaccination, lipid delivery, and coronavirus immunization is extensive.

Factor	Assessment
Core ionizable-lipid protection	Strong strategic value
Exact excipient combination	Potentially strong, depending on claim scope
Manufacturing protection	Important but difficult to assess externally
Method-of-use claims	Useful, but more exposed to validity challenges
Design-around potential	Moderate through alternative lipids and ratios
Biosimilar complexity	High because analytical and process similarity are demanding
Supply-chain defensibility	High for qualified GMP lipid production

Patent strength should not be inferred solely from the number of published applications. Continuations can preserve claim scope, while narrow issued claims may offer limited practical exclusion. A competitor’s actual risk depends on the claims that remain unexpired in the launch jurisdiction.

How does Spikevax compare with competing mRNA vaccines?

Attribute	Spikevax	Comirnaty
Sponsor	Moderna	Pfizer and BioNTech
Platform	mRNA in lipid nanoparticles	mRNA in lipid nanoparticles
Ionizable lipid	SM-102	ALC-0315
PEG-lipid	PEG2000-DMG	ALC-0159
Structural lipids	DSPC and cholesterol	DSPC and cholesterol
Regulatory pathway	BLA after EUA	BLA after EUA
Main patent risk	Moderna platform and lipid estate	Pfizer/BioNTech and third-party LNP estate
Key commercial differentiators	Dose, manufacturing network, formulation updates	Distribution scale, partnership structure, global supply

The products use similar functional architecture but different proprietary ionizable and PEG-lipid systems. That difference creates design-around opportunities while leaving both products exposed to overlapping third-party delivery patents.

What generic or biosimilar launch risks exist?

A direct Spikevax biosimilar launch faces five major risks:

1. The reference product’s biologic exclusivity delays approval timing.
2. Lipid nanoparticle patents may remain active after regulatory exclusivity ends.
3. Analytical similarity is difficult for a complex colloidal product.
4. Manufacturing process differences can affect potency and stability.
5. Updated seasonal formulations can create recurring regulatory and commercial requirements.

A practical entrant may choose an alternative mRNA vaccine with its own composition rather than pursue direct biosimilarity. That strategy can reduce dependence on Moderna’s exact formulation but increases development, clinical, regulatory, and market-access costs.

What licensing opportunities exist around Spikevax excipients?

Licensing opportunities are most likely to arise in three areas:

• Non-infringing ionizable lipids with demonstrated delivery performance.
• Thermostable or dried lipid nanoparticle formulations.
• Manufacturing processes that increase encapsulation efficiency or reduce solvent and lipid waste.

Public disclosures do not establish a single Spikevax-specific license covering every excipient. The relevant commercial analysis must distinguish Moderna-owned technology from third-party lipid nanoparticle patents, supplier know-how, manufacturing trade secrets, and contract manufacturing arrangements.

For licensors, the most valuable package combines composition claims, process claims, analytical methods, and GMP manufacturing support. A patent license without scalable supply or comparability data has lower practical value.

Key Takeaways

• Spikevax uses SM-102, PEG2000-DMG, DSPC, cholesterol, buffers, sucrose, and water for injection.
• SM-102 and the lipid nanoparticle architecture are the highest-value excipient assets.
• Spikevax is regulated as a biologic and is not protected through a conventional Orange Book listing.
• U.S. reference-product exclusivity generally runs from the January 31, 2022 BLA approval date, subject to the statutory framework.
• Paragraph IV is not the principal challenge mechanism for Spikevax; BPCIA litigation and ordinary patent actions are more relevant.
• Commercial opportunities center on ionizable-lipid supply, PEG-lipid alternatives, analytical testing, thermostability, and sterile manufacturing.
• The strongest design-around strategy is likely an alternative lipid nanoparticle composition with independent process and formulation patents.
• A direct biosimilar launch is more difficult than a new BLA for an independently formulated mRNA vaccine.

FAQs

Can SM-102 be replaced without creating a new product?

Yes, but replacing SM-102 would normally require extensive comparability, preclinical, manufacturing, and regulatory analysis. The replacement can alter potency, biodistribution, tolerability, particle size, and stability.

Are Spikevax excipients individually patentable?

Some excipients, especially proprietary ionizable lipids and PEG-lipids, can be protected by composition and use patents. DSPC, cholesterol, sucrose, and common buffers generally have less differentiated patent value unless used in a novel combination or process.

Is a Spikevax biosimilar the same as a generic mRNA vaccine?

No. A biosimilar must demonstrate high similarity to the reference biologic. An independently developed mRNA vaccine may use a separate BLA pathway and a different lipid nanoparticle composition.

Which excipient has the highest supply-chain risk?

The highest risk generally lies in specialized ionizable lipids, including SM-102, because they require complex synthesis, tight impurity control, and validated GMP production. PEG-lipids can also create bottlenecks during demand surges.

Can a room-temperature Spikevax formulation create a separate patent opportunity?

Yes. A formulation that maintains mRNA integrity, nanoparticle size, potency, and safety under less stringent storage conditions can support composition, stability, packaging, and manufacturing claims. Its commercial value depends on regulatory approval and demonstrated supply-chain savings.

References

European Medicines Agency. (2024). Spikevax: EPAR product information. https://www.ema.europa.eu/

Moderna, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.

U.S. Food and Drug Administration. (2024). Spikevax prescribing information. https://www.accessdata.fda.gov/

U.S. Food and Drug Administration. (2024a). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/

U.S. Patent and Trademark Office. (2020). U.S. Patent No. 10,702,600: Lipid nanoparticles for delivery of nucleic acids. https://patents.google.com/